Particle.news
Download on the App Store
9 ARTICLES
·
4w ago

AstraZeneca H1 Revenue Jumps 11% as It Pledges $50 Billion U.S. Expansion

Robust double-digit profit growth spurred a reassessment of a U.S. primary listing to strengthen its presence in the world’s largest biopharmaceutical market.

Image
FILE PHOTO: A company logo is seen at the AstraZeneca site in Macclesfield, Britain, May 11, 2021. REUTERS/Phil Noble/File Photo
Image
Cancer drug sales rose 18 per cent to $6.3 billion

Overview

  • Total revenue rose 11% to $28 billion in H1 2025, driven by double-digit growth in oncology and bio-pharmaceutical units.
  • Oncology sales made up 43% of H1 revenue, up 15% year-on-year, led by strong demand for treatments including Tagrisso and Imfinzi.
  • Core operating profit climbed 13% and earnings per share increased 17% to $4.66, surpassing analyst forecasts.
  • The company pledged $50 billion to expand U.S. manufacturing and research, earmarking its largest-ever facility in Virginia.
  • Pascal Soriot is exploring a shift of the primary listing to a U.S. exchange in response to U.K. regulatory and support concerns.